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Abstract 
 
Background: Epidemiological studies have suggested that female hormones might 
play a role in asthma and that menopausal hormone therapy (MHT or HRT) might 
increase the risk of asthma in postmenopausal women. The only prospective study 
addressing this issue reports an increase in the risk of developing asthma which was 
similar for estrogen alone and estrogen/progestagen treatment. 
Methods: The association between the use of different types of MHT and the risk of 
asthma onset in postmenopausal women was investigated prospectively from 1990 
to 2002 by biennial questionnaire as part of the French E3N cohort study. Asthma 
onset was considered to be the time of medical diagnosis of asthma cases occurring 
during the follow up of women who were asthma free at baseline. Cox proportional 
hazards models were used, adjusting for potential confounding factors. 
Results: Among 57,664 women free of asthma at menopause 569 incident cases of 
asthma were identified during 495,448 years of follow-up. MHT was related to an 
increased risk of asthma onset (HR= 1.20, 95% CI 0.98-1.46) among recent users. 
The increase in risk of asthma onset was only significant among women reporting the 
use of estrogen alone (HR= 1.54, 95% CI 1.13-2.09).particularly in never smokers 
(HR= 1.80 95% CI 1.15-2.80) and women reporting allergic disease prior to asthma 
onset (HR= 1.86 95% CI 1.18-2.93). A small increase in the risk of asthma onset 
associated with the use of estrogen/progestagen was also observed in these 
subgroups. 
Conclusion: Postmenopausal use of estrogen alone was associated with an 
increased rate of newly diagnosed asthma in menopausal women. 
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Introduction 
 
The major increase in asthma prevalence observed in most developed countries in 
recent years[1] suggests that it may in part be due to environmental factors. 
Differences in asthma incidence during the life cycle suggest that reproductive 
hormones influence the development of asthma and asthma severity.[2] Asthma is 
more frequent in girls after menarche than before.[3] Adult asthma and hospital 
admissions for asthma are more prevalent in women than in men and asthma 
severity has been shown to vary during the menstrual cycle and pregnancy.[4] In 
addition, the incidence of asthma tends to decrease after menopause.[5] The 
increase of asthma onset in postmenopausal women with increasing weight points to 
an endocrine mechanism such as increased endogenous estrogen synthesis.[6] 
Menopausal hormone therapy (MHT) might therefore play a role in asthma onset.    
Different studies have investigated the role of MHT in asthma. Cross-sectional 
studies have reported an association between prevalent asthma and asthma-like 
symptoms and MHT use in perimenopausal[7] and postmenopausal women,[8, 9] 
with a larger effect in lean women. However, these studies were cross-sectional and 
therefore could not evaluate the effect of MHT on asthma onset. None of these 
studies evaluated the risk related to different types of MHT. To date only one cohort 
study, the Nurses' Health Study, has suggested that MHT use is associated with an 
increased risk of developing asthma. It observed a similar significant (two fold) 
increase in risk with the use of estrogen alone or estrogen plus progestin.[2]  
The mechanisms underlying the link between hormonal factors and asthma risk are 
still not clearly understood.[10] Knowing whether MHT affects this risk and if so, 
whether different preparations have a similar effect, would provide a useful insight 
into the mechanisms by which the hormonal milieu acts on the airways. 
We used data from the E3N study, a large cohort of French women followed for over 
10 years, to evaluate the association between asthma onset and MHT use with 
special focus on the types of MHT and the duration of use. 
 
Methods 
 
Study population: the E3N cohort 
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E3N, a prospective cohort initiated in 1990, consists of 98,995 French women 
born between 1925 and 1950 and insured under a health insurance plan 
covering mostly teachers. The study was approved by the French National 
Commission for Data Protection and Privacy. E3N is the French component of 
the European Prospective Investigation into Cancer and Nutrition (EPIC). 
Participants, who gave written informed consent, completed biennial self-
administered questionnaires addressing medical history, menopausal status, 
and a variety of lifestyle characteristics.  
 
Definition of incident cases of asthma 
Women were considered incident cases of asthma if they stated at baseline 
(menopause) that they had never had an asthma attack and met the ATS 
criteria for asthma definition at follow-up ("Have you ever had asthma 
attacks?" and if yes “Was this diagnosis confirmed by a doctor?” ),[11] with a 
coherent reported age of asthma-onset (time of first attack between baseline 
and 2002).   
Identification of MHT use 
Information on lifetime use of hormonal treatments was first recorded in the 1992 
questionnaire. For each episode of treatment (defined as the non-stop use of the 
same hormonal brand or combination), brand name, age at initiation of use and 
duration were recorded. The information was updated in each of the subsequent 
questionnaires. The complete history of MHT use was established using data from all 
the questionnaires. MHT use was categorized by i) type of estrogen: weak estrogens 
(orally or vaginally administered promestriene or estriol) or estradiol compounds 
(unopposed MHT consisted almost exclusively of estradiol compounds; only 1.3% of 
women ever used conjugated equine estrogens (CEEs) corresponding to 8% of the 
total  person years of follow up and ii) type of oral progestagen used in association 
with the estrogen: none, micronized progesterone, pregnane or norpregnane 
derivatives, and testosterone derivatives.  
 
  
Body mass index 
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Body mass index (BMI) was calculated from the height and weight self-
reported in each questionnaire. BMI was used in the different analyses as a 
continuous or categorical time-dependent variable. Information on 
anthropometric measurements provided by our questionnaire have been 
shown to be highly reliable.[12] 
 
Other information 
Information on tobacco smoking was reported in each questionnaire and respondents 
were categorized as never, past, regular or occasional smokers. The last two 
categories were combined into a "current smokers" category. Atopy was defined as  
present if the woman reported  diagnosis of allergic rhinitis, eczema or any other 
allergic disease on the questionnaire prior to asthma 2002. 
 
Population for analysis and follow-up 
Our analysis was based on 57,664 postmenopausal women, corresponding to 
495,448 person-years of follow-up. These women were free of asthma at inclusion 
and all subsequent self-reports of asthma onset were validated according to the ATS 
criteria. Subjects contributed person-time until the date of the first asthma attack or 
July 2002 (date of dispatch of the seventh questionnaire), whichever occurred first. 
 
Figure 1 presents a diagram of the initial population, the reasons for exclusion 
and the population included in the analysis.  
 
Statistical analysis 
Hazard ratios (HRs) for asthma were estimated using Cox proportional hazards 
models, with age as the time scale. We adjusted our model for tobacco smoking and 
BMI  included in the model as time-dependent[or time-varying] covariables , and for 
other risk factors. MHT use was included in the model as a time-dependent variable. 
A woman contributes  to person year of ever use from the date she starts her 
treatment to the end of  the follow up, contributes to person year of recent use from 
the date she starts her treatment to 1.5 years after she stops and contributes to 
person year of past user thereafter. This cutoff (1.5 years) was chosen because 65% 
of the cases occurring after cessation of MHT use did so within a year and a half of 
cessation. The reference group in each model consisted of women who indicated 
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that they had not used yet any MHT. Further analyses were conducted after 
stratification of the data by hysterectomy, type of menopause (surgical non surgical), 
smoking status as well as the atopic status of the women. All tests of statistical 
significance were two sided, and significance was set at the 0.05 level. All analyses 
were performed using SAS software, version 9.1 (SAS Institute Inc., Cary, North 
Carolina) (for further details of methods used, see the online supplement). 
 
Results 
Among the 57,664 women who reported being postmenopausal and had information 
on MHT use, there were 569 incident cases of asthma between 1992 and 2002, 
corresponding to an incidence of 1.15/1000 per year.  
 
Never user of MHT accounted for 35.7% of the person-years, past users for 4.5%, 
recent users for 55.8%, and 4% did not provide information on duration of treatment. 
The mean age of ever users and never users at the start of follow-up was 52.25 
years (SD=4.00) and 54.58 years (SD=4.74) (p<0.0001) respectively. Women 
excluded from the analysis were less likely to have used MHT or oral contraceptives, 
and were slightly older and had a larger BMI (chi2 test p-value <.001) than those 
included. 
 
Table 1 presents the characteristics of ever users and never users of MHT included 
in the analysis. After adjusting for age, ever users were more likely to have a lower 
BMI (p<0.001) and to have ever used oral contraceptive (p<0.0001) than never 
users.  
 
Surgical menopause was reported by 10% of the women. The use of estrogen alone 
was reported by 9.4% of the women with natural menopause and by 28.1% of the 
women with surgical menopause. Hysterectomy was reported by 19% of the women. 
Among women who had an hysterectomy 58% reported a natural menopause and 
27% a surgical menopause (n=2986), 36% of these reported using estrogen alone 
(see online supplement). 
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The HR of asthma onset among women who had ever used MHT was 1.21 (95% CI 
1.00-1.46) compared to never users after adjusting for age, smoking, BMI, oral 
contraceptive use, parity and total caloric intake (Table 2).   
 
The HR Among recent MHT users  the HR was 1.20 (95% CI 0.98-1.46), and  was 
1.16 (95% CI 0.86-1.57) among past users. Women who reported using MHT for less 
than 2 years had a HR of 1.25 (95% CI 1.02-1.53) and those who reported using 
MHT for two years or more a HR of 1.09 (95% CI 0.85-1.38), compared to never 
users (Table 2).  
 
Estrogen alone was reported as the last treatment used by 11.2% of the women. 
These women were at higher risk of asthma onset (HR=1.54, 95% CI 1.13-2.09) 
compared to never users. The risk was not significantly increased among women 
who reported estrogen/progesterone (18.3%), a combination of estrogen and another 
progestagen (54.7%) or another MHT (15.8%) as the last treatment used. In 
subsequent analyses, users of any type of estrogen-progestagen were therefore 
combined into an “estrogen/progestagen users” category. The risk of asthma onset 
associated with the use of estrogen alone was significantly different from that 
associated with the use of estrogen/progestagen (test for homogeneity p=0.04). The 
route of estrogen administration (oral or transdermal) did not significantly affect the 
risk (Table 2). 
 
For recent users of estrogen alone the HR of asthma onset was 1.67 (95% CI 1.20-
2.27), while for past users it was 1.04 (95% CI 0.51-2.12). Among women who 
reported using estrogen alone for less than 2 years the HR was 1.60 (95% CI 1.12-
2.27) while among those who reported using estrogen alone for 2 years or more the 
HR was 1.39 (95% CI 0.84-2.31). These HRs were non significantly different (test for 
homogeneity p=0.63). The route of administration of estrogens without progestagen 
did not affect the risk. Among women reporting the use of estrogen/progestagen 
there was no indication of an increase in the risk of asthma onset whatever the 
duration or recency of use or route of estrogen administration (Table 3). 
 
Among never smokers, MHT use was significantly related to the risk of asthma onset 
(HR=1.45, 95% CI 1.10-1.90) while among smokers the HR was 1.02 (95% CI 0.79-
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1.31) (test for interaction p=0.09) (see  online supplement Table E1). Among women 
who reported using estrogen alone, the HR was 1.80 (95% CI 1.15-2.80) for never 
smokers and 1.31 (95% CI 0.85-2.03) for ever smokers (test for interaction p=0.37). 
Never smokers using estrogen/progestagen had a HR of 1.38 (95% CI 1.02-1.86), 
while no effect (HR=0.92, 95% CI 0.69-1.21) was observed in ever smokers (test for 
interaction p= 0.16) (Table 3). 
 
Higher BMI was associated with an increased risk of asthma onset (p for trend 
<0.001) but there was no indication of an interaction between MHT use and BMI on 
the risk of asthma (p=0.45). Among women with a BMI less than 22 the HR of 
estrogen alone users was 1.25 (95% 0.65-2.40); among women with a BMI from 22 
to 25, the HR was 1.67 (95% CI 0.93-3.01) and among women with BMI>25 the HR 
was 1.54 (0.99-2.39). 
 
After stratification by the presence of hysterectomy or the type of menopause we 
observed  a  small increased risk in non hysterectomized women using estrogen 
alone and  among women declaring a natural menopause , although the small 
number of cases in some of the subgroups limited the interpretation of the results 
(see online supplement tables E2 and E3) 
 
Women who reported a diagnosis of allergic disease prior to asthma onset appeared 
to have a larger risk of asthma related to MHT than their counterpart.. An increased 
risk of asthma was present for the use of estrogen alone (HR = 1.86 (95% CI 1.18-
2.93) and  a marginal significant increase was observed for the use of 
estrogen/progestagens (HR=1.39 95% CI 1.01-1.91)  in women with allergic disease 
as compared to women without allergic disease (Table 4). 
 
 
Discussion 
In this large prospective study of French women including 569 incident cases of 
asthma over 495,448  person-years, use of estrogen alone as last treatment was 
significantly associated with an increased risk of asthma  onset in postmenopausal 
women, after adjustment for potential confounding factors. The increase in risk was 
mostly observed among women reporting an allergic disease prior to asthma onset 
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and never smokers. In these subgroups, the risk of asthma onset was  strongly 
related to the use of estrogen alone and  a marginal association was observed with 
the use of  estrogen/progestagens.  
 
Our results agree in part with other recent reports. In the Nurses' Health Study 
(NHS), MHT use was significantly related to the risk of asthma onset  in 
postmenopausal women. However, a similar increased risk was reported for both 
estrogen alone and estrogen/ synthetic progestin. The effect was stronger in current 
users, and the risk diminished with time after cessation. In addition, an interaction 
was observed between MHT and BMI, with a larger risk of newly diagnosed asthma 
in lean women.[2] 
 
In the cross-sectional Copenhagen City Heart Study, the prevalence of self-reported 
asthma was significantly related to MHT in non-smokers.[9] Two further recent cross-
sectional studies reported an association between prevalent asthma and asthma-like 
symptoms with MHT use in women aged 46-54[7] and postmenopausal women,[8] 
but only in lean women. None of these cross-sectional studies provided information 
on the type of HRT used. 
 
In our study, the increased risk of asthma onset among women using MHT was 
present only in users of estrogen alone. The effect was observed only in recent users 
including current users and women for whom time since last use was less than 1.5 
years. Overall no increased risk was observed in users of estrogen/progestagen 
while a marginally significant increase was observed among women reporting a 
diagnostic of allergic disease prior to asthma onset and among non smokers.  
 
Our study and the NHS are comparable in design, number of cases and person 
years of follow up. Results of both studies agree on the adverse effect of estrogen 
alone MHT; however we observed conflicting results with regards to 
estrogen/progesterone MHT in the overall analysis. The marginal increased risk 
observed in some subgroups of our population is difficult to compare given that no 
stratified data on smoking or allergic disease are presented in the report from the 
NHS.[2] 
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Several mechanisms have been proposed to explain the role of female hormones in 
asthma risk. However, there is still some uncertainty. Estrogen appears to have both 
anti- and pro-inflammatory effects, depending on criteria such as cell types, 
conditions in the milieu, estrogen concentration and the target organ.[13] While 
estrogen may have a pro-inflammatory effect regulating the response to allergens, it 
may also down-regulate the traffic of eosinophils to the lung during the effect or 
phase of the response to antigens.[14] It has also been shown that estrogen acts to 
down-regulate airway hyperresponsiveness in a dose-dependent manner and 
relatively rapid, nongenomic manner by enhancing the activity of endothelial nitric 
oxide synthase.[15] Several animal studies have reported increased susceptibility to 
allergic airway disease in female mice compared to male mice. Estrogens appear to 
exert most of their effects through estrogen receptors alpha and beta, both of which 
are present in the lung.[10] Ovariectomized rats developed less airway inflammation 
than controls and estrogen replacement re-established airway inflammation to the 
level found in intact females. A recent study suggested that female rats have fewer 
Treg cells and therefore less protection against inflammatory stimuli such as 
allergens.[16] Estrogen (estradiol) has also been shown to alter beta-2-adrenergic 
responsiveness[17] and to activate endothelial nitrite oxide synthase,[18] involved in 
the pathogenesis of asthma. Estrogen is capable of inhibiting the activity of 11β 
hydroxysteroid dehydrogenase type I isoenzyme; thereby reducing its ability to 
regenerate active cortisol from cortisone, and cortisol is an extremely powerful anti-
inflammatory agent that may be protective against the development of chronic 
inflammation.[19] Finally, estrogen levels have been related to lower levels of 
adiponectin, a protein that is secreted exclusively by adipocytes, acts as insulin 
sensitizer and has anti-inflammatory properties.[20] This citokyne is inversely 
associated with fat mass and insulin resistance and has been proposed as a link 
between obesity and inflammation in humans.[21] Most likely several of these 
mechanisms and pathways play a role and interact with individual susceptibility. 
 
Unopposed estrogens are used in women who have had a hysterectomy, and 
hysterectomy may lead to hormonal changes and respiratory morbidity, or 
alternatively a common underlying pathology may lead both to gynecological 
morbidity resulting in hysterectomy and to asthma.[8]In our data, among MHT never 
users, the HR of asthma onset associated with hysterectomy was 1.31 (95% CI 0.85-
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2.01) suggesting that hysterectomy could not fully explain the increased risk 
observed among the estrogen users. Only 38.8% of women with hysterectomy 
reported using estrogen alone and the reason for hysterectomy was unknown. In 
stratified analyses by hysterectomy or type of menopause, there was no indication of 
differential effects of MHT in these subgroups.  
 
We did not observe a clear increase in the risk of asthma onset with 
estrogen/progestagen treatment in contrast to the results of the Nurses´ Health 
study.  In our population, a marginal  increased  risk was restricted to never smokers 
and women who reported a diagnostic of allergic disease prior to asthma onset . 
While we do not have a clear explanation for this,  combined HT regimen have been 
shown to positively affect the lung functions of postmenopausal women while 
estrogen alone has no effect.[22] Progesterone has receptors in the lungs and 
trachea and can therefore have local effects at these sites and cause ventilatory 
stimulation via chemoreceptor activity.[23] In a rat model of allergic lung 
inflammation, estradiol increased the number of neutrophils, eosinophils, and 
mononuclear cells in the bronchoalveolar lavage of ovariectomized allergic rats, 
whereas progesterone induced an additional reduction. Degranulation of bronchial 
mast cells from ovariectomized rats was reduced after in vitro challenge, an effect 
reverted by estradiol but not by progesterone.[24] These authors suggest that 
intensity of allergic lung inflammation might be related to the estradiol-to-
progesterone ratio at the time of immune sensitization and antigen challenge. 
Exogenous progesterone might also down-regulate beta2-adrenoceptors, which 
would explain part of the difference between MHTs.[17] A possible explanation for 
the difference of effect observed between the NHS and our study could be the 
difference in  the type of progestorene used by Us and French women and /or the 
ratio of estrogen-to progesterone. In the US combined  MHT uses mostly 
medroxyprogesterone acetate (MPA) while in our study this type of treatment 
represented only 10.2% of person years of FU. Micronized progesterone 
corresponding to 19.7% and other pregnane and norpregnane derivatives to 38.3%.   
 
The association of MHT use with increased risk of asthma onset was more apparent 
among never smokers, as reported in other studies.[7, 9] This might be due to the 
anti-estrogenic effect of smoking[25] or to the difficulty of isolating the additional 
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effect of MHT among smokers. In contrast to other studies, we did not observe an 
interaction between BMI and MHT use.[2, 7, 8] An earlier analysis of our data found a 
significant association between BMI and the risk of asthma onset in both MHT ever 
users and never users.[6] The lack of interaction in our data might be due to the BMI 
distribution of our population, which was leaner than that of the Nurse’s Health Study.  
 
Women reporting a diagnostic of allergic disease prior to asthma onset had a higher 
risk of MHT related asthma than their counterpart. A crossectional study among 
English women Jarvis et al[8] reported that current use of HRT was related to 
wheeze but not related to markers of allergy (IgE). No data on atopic asthma was 
presented. Our data suggest that women with allergic predisposition might be more 
susceptible to the effect of MHT in developing asthma. However, these results should 
be interpreted with caution given the small number of cases in some subgroups and 
the potential misclassification of allergic disease based only on women’s reports at 
baseline and in the follow up questionnaires. 
 
The strengths of our study include the large number of postmenopausal incident 
cases of asthma. While we imputed age at menopause for some women with missing 
information (n=9,585), results remained similar when these women were excluded 
from the analysis. Information on current and past MHT use was updated every two 
years, decreasing the potential risk of misclassification of MHT. In our analysis, we 
used the information relating to the hormone therapy at the time of asthma onset. 
Fifty eight percent of women reporting the use of estrogen alone at the time of 
asthma onset or as last treatment before asthma onset had previously used another 
MHT. This supports our finding that the increased risk of asthma onset is linked to 
estrogen use. We also conducted additional analyses in which exposure was defined 
as exposure to the MHT with the longest duration of use. Results remained similar. 
For 80.5% of the women, the last treatment used was also the longest. In addition, 
most participants in the E3N cohort were teachers, with a high level of education and 
health-consciousness,[26] while the prospective design and high rate of follow-up of 
our study (3.8% lost to follow-up) minimized the possibility of recall bias or bias due 
to loss of follow-up. 
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Our definition of asthma met the ATS criteria, and there was a consistent reported 
date of asthma onset (time of first attack between 1990 and 2002). In addition, we 
conducted an analysis including as asthma cases only women who reported having 
asthma in at least two questionnaires (persistent asthma). Results were similar to 
those observed when all cases of asthma onset were included. Some women may 
suffer not from asthma but from chronic obstructive pulmonary disease (COPD). We 
did not measure pulmonary function so the possibility of COPD in older women, 
particularly ex- and current smokers, cannot be excluded. However, 51% of the 
cases were non-smokers and were therefore unlikely to have COPD. Furthermore, 
asthma risk was related to MHT use in non-smokers suggesting that neither smoking 
nor the misclassification of asthma as COPD could explain the association observed 
between MHT and asthma incidence. In the Nurses' Health Study, MHT was not 
related to newly diagnosed COPD.[2] 
 
Our results could be biased if MHT users systematically reported more asthma 
attacks or if asthma was diagnosed more often in MHT users because of more 
frequent doctor visits. During the follow up, 93% of the MHT users had a 
mammogram versus 78% of the non users. However, our population had access to 
free medical care and there is no reason to believe that MHT users make more 
frequent medical visits than non-users for non gynecological related health issues.  
 
In conclusion, our study shows an association between the use of estrogen alone as 
MHT and asthma onset in a large cohort of postmenopausal women. This effect 
might be linked to an increase in airway inflammation mediated by different 
pathways, such as inflammatory cytokine release or stimulation of NO synthesis. The 
increase in asthma risk associated with MHT must be judged in the light of all other 
health effects of MHT use taking including its beneficial effect on the quality of life of 
menopausal women. 
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Table 1. Characteristics of the study population (n= 57,664), E3N cohort study. 
 
 
  
Never user of 
MHT 
N=16138 
Ever user of 
MHT 
N=41526 
p* 
BMI (kg/m2)    
   <.0001 
<20  1713 (10.72%) 5114 (12.26%)  
20 - 22 3299 (20.65%) 10363 (24.85%)  
22 - 22 5327 (33.35%) 15425 (36.99%)  
>25 5632 (35.28%) 10791 (25.90%)  
    
Tobacco use†    
   0.19 
Never smoker 9601 (60.20%) 23023 (55.28%)  
Ex-smoker 4918 (30.83%) 14484 (34.78%)  
Current smoker 1429 (8.97%) 4134 (9.94%)  
    
Caloric intake (kcal/d) †    
   0.84 
<1760 3393 (26.06%) 8196 (23.20%)  
1760 - 2112 3293 (25.29%) 8918 (25.25%)  
2112 - 2513 3167 (24.32%) 9128 (25.84%)  
>2513 3166 (24.33%) 9071 (25.71%)  
    
Pregnancy    
   0.06 
Nulliparous 2293 (14.35%) 4574 (10.97%)  
<=2 children 8766 (54.88%) 25257 (60.57%)  
>2 children 4912 (30.77%) 11862 (28.46%)  
    
Oral contraceptive use   
 18
   <.0001 
Never 8269 (51.77%) 14562 (34.92%)  
Ever 7702 (48.23%) 27131 (65.08%)  
    
Menopausal status†   
   <.001 
Natural 13213 (86.78%) 36593 (90.45%)  
Surgical 2013 (13.22%) 3862 (9.55%)  
    
   <.0001 
Natural   
estrogen alone  3459 (67.48%)  
Surgical  
estrogen alone  1086 (21.19%)  
* p-value from age adjusted logistic regression for assessing differences 
between users and never users 
† Missing data not shown (tobacco use 0.1% caloric intake 16.2%; menopausal 
status: 3.4%) 
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Table 2. Hormone therapy and asthma onset among postmenopausal women, E3N 
cohort study 
 
Cases 
Person- 
year 
Multivariate-adjusted* 
  hazard ratio (95% CI) 
Never use 186 177029 1 
Use† 383 318419 1.21 (1.00 - 1.46) 
Recency‡    
Recent 283 276506 1.20 (0.98 - 1.46) 
Past 73 22294 1.16 (0.86 - 1.57) 
Duration‡    
< 2 yrs 236 104607 1.25 (1.02 - 1.53) 
2 + yrs 120 194193 1.09 (0.85 - 1.38) 
Type of treatment‡     
Estrogen alone 55 33426 1.54 (1.13 - 2.09) 
Estrogen-progesterone 67 58978 1.13 (0.85 - 1.51) 
Estrogen-norPregnane derivate 52 54616 1.01 (0.74 - 1.38) 
Estrogen-pregnane derivative§ 103 89663 1.13 (0.88 - 1.46) 
Estrogen-testosterone derivative 20 14882 1.36 (0.86 - 2.15) 
Other  59 47235 1.22 (0.90 - 1.66) 
Estrogen route**,‡     
Oral 88 65476 1.26 (0.97 - 1.65) 
Transdermal 209 187794 1.15 (0.93 - 1.41) 
*  Adjusted for tobacco use (never smoker / current smoker / past smoker / missing 
information), BMI (kg/m2), ever use of oral contraceptive (yes / no), parity 
(nulliparous / 2 or fewer full term pregnancies / more than 2 full term pregnancies / no 
information), total caloric intake (kcal/day), type of menopause (natural / surgical / 
unknown), further stratified by year of birth ([1925-1929]/[1930-1934]/[1935-
1939]/[1940-1944]/[1945-1950]. 
† Women whose age of start of MHT is missing are excluded. 
‡ Women without any information other than age of start of MHT are excluded. 
§ As part of Pregnane derivatives, dydrogeterone users (HR: 1.06 95% CI: 0.75 - 
1.48) accounted for 41795 PY and 43 cases of asthma. 
 20
Tibolone, weak estrogen (unopposed or not), estrogen/testosterone, progestin only 
and unknown MHT. 
** Combined or not with a progestagen. P for heterogeneity 0.45. Nasal estrogen, 
weak estrogen, other HT and unknown HT not shown  
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Table 3. Hormone therapy and asthma onset among postmenopausal women by 
type of treatment, E3N cohort study  
 
* Cases 
Person- 
year 
Multivariate adjusted†   
Cases 
Person-
year 
Multivariate-adjuste
Hazard Ratio (95% CI) hazard ratio (95% C
 Estrogen alone Estrogen-Progestagens‡   
Recency        
Recent 41 29035 1.67 (1.20 - 2.32) 208 210608 1.14 (0.92 - 1.40)
Past 14 4391 1.04 (0.51 - 2.12) 34 7531 0.97 (0.64 - 1.46)
Duration        
< 2 yrs 38 13760 1.60 (1.12 - 2.27) 159 67671 1.20 (0.96 - 1.50)
2 + yrs 17 19666 1.39 (0.84 - 2.31) 83 150468 0.99 (0.76 - 1.30)
Estrogen route§‡      
Oral 10 5367 1.78 (0.93 - 3.38) 78 59791 1.21 (0.92 - 1.60)
Transdermal 45 28006 1.50 (1.07 - 2.09) 163 158263 1.08 (0.86 - 1.34)
Smoking Status       
Never Smoker 28 31724 1.80 (1.15 - 2.80) 128 122585 1.38 (1.02 - 1.86)
Ever smoker 27 14273 1.31 (0.85 - 2.03) 114 95342 0.92 (0.69 - 1.21)
*  Women without any information other than age of start of MHT are excluded. 
† Adjusted for tobacco use (never smoker / current smoker / past smoker / missing 
information), BMI (kg/m2), ever use of oral contraceptive (yes / no), parity (nulliparous 
/ 2 or fewer full term pregnancies / more than 2 full term pregnancies / no 
information), total caloric intake (kcal/day), type of menopause (natural / surgical / 
unknown), further stratified by year of birth ([1925-1929]/[1930-1934]/[1935-
1939]/[1940-1944]/[1945-1950]. 
‡ Progestagens include: progesterone, pregnane derivatives, norpregnane 
derivatives and testosterone derivatives.   
§ Combined or not with a progestagen. Nasal estrogen, weak estrogen, other HT and 
unknown HT not shown  
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Table 4. Hormone therapy and asthma onset among postmenopausal women by 
atopic status, E3N cohort study 
 
  Multivariate -adjusted† Multivariate-adjusted†
  
PY 
non atopic (306 cases) atopic (251 cases) 
* cases HR 95%CI cases HR 95%CI 
Never use 177029 114 1 67 1 
Use 318419 192 1,04 (0,81 - 1,33) 184 1,52 (1,13 - 2,05
Recency      
Recent 276506 137 1,02 (0,79 - 1,33) 139 1,52 (1,11 - 2,07
Past 22294 41 1,04 (0,69 - 1,56) 32 1,42 (0,90 - 2,25
Duration      
< 2 yrs 104607 123 1,11 (0,84 - 1,45) 110 1,55 (1,12 - 2,13
2 + yrs 194193 55 0,88 (0,63 - 1,22) 61 1,42 (0,98 - 2,05
Type of treatment‡      
Estrogen alone 33426 29 1,43 (0,96 - 2,11) 25 1,86 (1,18 - 2,93
Estrogen-progestagens 218139 122 0,98 (0,75 - 1,28) 114 1,39 (1,01 - 1,91
Other  47235 27 0,97 (0,64 - 1,47) 32 1,76 (1,16 - 2,68
Estrogen route§‡,      
Oral 65476 44 1,19 (0,84 - 1,69) 42 1,56 (1,05 - 2,33
Transdermal 187794 107 1,01 (0,77 - 1,33) 97 1,43 (1,04 - 1,97
 
*Women without any information other than age of start of MHT are excluded. 
 
 †Ajusted for tobacco use (never smoker / current smoker / past smoker / missing 
information), BMI (kg/m2), ever use of oral contraceptive (yes / no), parity (nulliparous 
/ 2 or fewer full term pregnancies / more than 2 full term pregnancies / no 
information), total caloric intake (kcal/day), type of menopause (natural / surgical / 
unknown), further stratified by year of birth ([1925-1929]/[1930-1934]/[1935-
1939]/[1940-1944]/[1945-1950]. 
‡ Progestagens include: progesterone, pregnane derivatives, norpregnane 
derivatives and testosterone derivatives. 
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Tibolone, weak estrogen (unopposed or not), estrogen/testosterone, progestin only 
and unknown MHT. 
§ Combined or not with a progestagen. Nasal estrogen, weak estrogen, other HT and 
unknown HT not shown  
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Figure 1. Diagram of the initial population, the reasons for exclusion and the 
population included in the analysis.   
E3N Population :
N=98,995
Population of analysis:
N=81,455
n=17,540
Excluded because did not answer the 
seventh questionnaire in which self-
reports of asthma onset were validated 
according to the ATS criteria 
Population of analysis:
N=77,217
n=4,238 Excluded because still premenopausal at end of follow-up
Population of analysis:
N=74,400
n=2,817
Excluded because did not answer the 
second questionnaire  (reason: no 
information on lifetime use of MHT)
Population of analysis:
N=62,021
n=12,379
Excluded because information on 
asthma status according to ATS criteria 
was missing
Population of analysis:
N=58,851
n=3,170 Excluded because of diagnosis of asthma before start of follow-up
Population of analysis:
N=57,664
n=1,187 Excluded because the age at first use of MHT was missing
